At Zeal Bio, Alan Bash recommended shutting down operations when the science failed to show sufficient conviction for investors. This tough but pragmatic decision, made sooner rather than later, was respected by investors as it prevented further capital loss on a non-viable program.

When Applovin's stock fell 92%, the market signaled the business was doomed. The CEO's most critical job was to maintain and project internal conviction in a new, bold strategy (rebuilding their core tech). This confidence was essential to rally the team and retain the key talent needed for a turnaround.

When facing a crisis, Fibrogen's CEO decided to shut down discovery research programs. The value inflection opportunity was too far in the future, and capital was better spent on assets with the potential to create more near-term value, ensuring the company's survival.

While scientific acumen is valuable, the most critical trait for a biotech CEO is perseverance. The role involves weathering constant challenges where everyone—the board, investors, employees—can seem to be against you. An unwavering focus on the patient mission is essential to push through.

While fundraising in a collapsing market, Turbine's CEO faced immense pressure to pivot from a platform to a traditional biotech model. He credits their survival and success to sticking to their core vision, managing cash aggressively, and having the mental resilience to resist deviating.

Beyond scientific knowledge, the most effective biotech CEOs possess a specific set of traits. They must be decisive, maintain ruthless capital discipline (even for small amounts), and consistently demonstrate strategic clarity, especially when facing the immense pressure inherent in the industry.

CellSci CEO Gerd Kirsten, a lawyer and financier, argues his primary function is protecting the company from market manipulation. He contends that his law and finance background has been more critical for survival than scientific expertise, which is useless without funding.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.

While success is celebrated publicly, some of the best leadership happens privately when a CEO makes the tough, candid call to shut down a program or company due to unfavorable data. This "truth-seeking" decision, often against their personal interest, is a hallmark of excellence.